BridgeBio Oncology Therapeutics Inc.
General ticker "BBOT" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $225.2M (TTM average)
BridgeBio Oncology Therapeutics Inc. does not follow the US Stock Market performance with the rate: -20.2%.
Estimated limits based on current volatility of 1.4%: low 3.92$, high 4.03$
Factors to consider:
- Total employees count: 92 as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Clinical trial failure, Regulatory and compliance, Limited operating history, Capital raising, Product liability claims
- Current price 51.4% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [8.00$, 17.83$]
- 2026-12-31 to 2027-12-31 estimated range: [5.67$, 13.38$]
Short-term BBOT quotes
Long-term BBOT plot with estimates
Financial data
| YTD | 2024-12-31 | 2025-12-31 |
|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM |
| Operating Expenses | $80.86MM | $145.82MM |
| Operating Income | $-80.86MM | $-145.82MM |
| Non-Operating Income | $6.59MM | $11.78MM |
| R&D Expense | $73.11MM | $121.20MM |
| Income(Loss) | $-74.28MM | $-134.04MM |
| Net Income(Loss)* | $7.60MM | $-134.04MM |
| Stockholders Equity | $-3.73MM | $411.10MM |
| Assets | $194.42MM | $448.38MM |
| Operating Cash Flow | $-0.76MM | $-113.89MM |
| Capital expenditure | $0.00MM | $0.61MM |
| Investing Cash Flow | $-184.00MM | $73.33MM |
| Financing Cash Flow | $186.46MM | $383.40MM |
| Earnings Per Share** | $588.97 | $-4.30 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.